TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28279484
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg per day)
Study: 28279484
Drug: Prednisolone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.5 mg/kg per day)
Study: 26164786
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg/valsartan 80 mg (L10/V80)
Study: 26164786
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg/valsartan 160 mg (L10/V160)
Study: 26164786
Drug: Lercanidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 20 mg/valsartan 160 mg (L20/V160)
Study: 26164786
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg (L10)
Study: 21641636
Drug: Cetuximab added
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab added to oxaliplatin and fluoropyrimidine chemotherapy (arm B)
Study: 21641636
Drug: Oxaliplatin and
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and fluoropyrimidine chemotherapy alone (arm A)
Study: 19209478
Drug: Thoracic spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic spine thrust manipulation plus electro-thermal therapy for 5 treatment sessions
Study: 19209478
Drug: Electro-thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-thermal therapy for 5 treatment sessions
Study: 16416224
Drug: pantoprazole, 40
Normalized name: Pantoprazole, 40 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole, 40 mg
Study: 16416224
Drug: omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole, 20 mg
Study: 9366668
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant exchange (second implant)
Study: 9366668
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant exchange (third implant)
Study: 3895098
Drug: Chemoimmunotherapy (CIT:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (CIT: plus allogeneic Neuraminidase‐treated blasts in high dosage)
Study: 3895098
Drug: Cyclic chemotherapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic chemotherapy (CT) alone
Study: 3895098
Drug: Chemoimmunotherapy (CIT)
Normalized name: Cit
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoimmunotherapy (CIT) for patients receiving more than 2 cycles of maintenance therapy
Study: 31211327
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Therapy
Study: 20154337
Drug: Eprosartan on
Normalized name: Eprosartan only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan on top of other anti-hypertensive drugs (n = 47)
Study: 20154337
Drug: Other anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anti-hypertensive drugs alone (n = 50)
Study: 14870884
Drug: Bicarbonate/lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate solution (25 mmol/L bicarbonate and either 10 or 15 mmol/L lactate)
Study: 14870884
Drug: Bicarbonate/lactate 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate 35 mmol/L
Study: 14870884
Drug: Higher calcium
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher calcium (1.75 mmol/L) lactate/bicarbonate solution
Study: 14870884
Drug: Standard lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lactate solutions (35 or 40 mmol/L)
Study: 15251661
Drug: Insulin doses
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin doses greater than 30 units
Study: 6895626
Drug: sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate (1 g, 0.5 h before each meal and at bedtime)
Study: 6895626
Drug: cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (300 mg, 0.5 h before each meal and at bedtime)
Study: 29949505
Drug: Ethanol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (120 ml of vodka followed by 60 ml of vodka)
Study: 28444115
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm with more responders
Study: 17121590
Drug: BDP HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP HFA 100 microg twice daily
Study: 17121590
Drug: BDP CFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP CFC 100 microg twice daily
Study: 17121590
Drug: BDP CFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP CFC 200 microg twice daily
Study: 17121590
Drug: Inter-period comparisons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inter-period comparisons of active treatments
Study: 15085875
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment and best supportive care
Study: 11346432
Drug: Oral DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral DFMO at daily dosages between 0.075 and 0.4 g/m(2) for 12 months
Study: 9720660
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg qd p.o. for 4 consecutive days starting 2 days before immunization)
Study: 4694690
Drug: New Lanoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Lanoxin tablets
Study: 4694690
Drug: Old Lanoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old Lanoxin tablets
Study: 30576772
Drug: BT-11 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT-11 (300 mg daily)
Study: 27183377
Drug: Hydroxychloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 mg oral twice daily) plus pegylated interferon alfa‐2a (160 μg subcutaneous once weekly) plus ribavirin (1000–1200 mg/day) for 12 weeks
Study: 27183377
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy (pegylated interferon alfa‐2a plus ribavirin) for 12 weeks
Study: 19462921
Drug: Fluroben 100
Normalized name: Fluroxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluroben 100 mg tablet
Study: 19462921
Drug: Originator product
Normalized name: Sucrets Original Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator product 100 mg tablet
Study: 17993031
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily varnish application (G1)
Study: 17993031
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily varnish applications with a 15-minute interval (G2)
Study: 17993031
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily varnish applications with a 5-hour interval (G3)
Study: 17993031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (G4) - no varnish treatment
Study: 11054515
Drug: Sulphasalazine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (500 mg, two tablets twice daily)
Study: 28158151
Drug: 0.075% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% capsaicin cream
Study: 3856501
Drug: Isotretinoin 80
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin 80 mg
Study: 3856501
Drug: Isotretinoin 160
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin 160 mg
Study: 3856501
Drug: Isotretinoin 240
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin 240 mg
Study: 3856501
Drug: Isotretinoin 320
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin 320 mg
Study: 25889643
Drug: Polydextrose (PDX)
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX) 12.5 g or 15 g
Study: 9222648
Drug: Tolbutamide treatment
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolbutamide treatment for approximately 10 years
Study: 31420055
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg) + Oxycodone (10 mg)
Study: 31420055
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg) only
Study: 29415828
Drug: Bacillus cereus
Normalized name: Bacillus cereus
DrugBank: Bacillus cereus (DB19245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus cereus A 05 (4 vials with 5 mL × 10^6 every 6 hours)
Study: 29415828
Drug: Soluble fiber
Normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fiber (10 g every 8 hours)
Study: 25153575
Drug: l-thyroxine (l-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: l-thyroxine (l-T4) supplementation at a dose of 5 μg/kg/day
Study: 25153575
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (no l-T4 supplementation)
Study: 20890243
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone for 3 days postoperatively (Group 1)
Study: 20890243
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic steroid treatment (Group 2)
Study: 14982551
Drug: High-dose fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluoxetine (60 mg)
Study: 14982551
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for smoking cessation
Study: 9572066
Drug: L-carnitine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (5 grams intravenously over 2 hours, twice daily for 5 consecutive days; 10 grams in 1500 ml cardioplegia administered through the aortic root after aortic cross-clamping)
Study: 10150550
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus diazepam
Study: 27654496
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for child PTSD
Study: 26727041
Drug: Metyrapone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (500 mg twice daily)
Study: 25523407
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (fluid, with and without dobutamine)
Study: 22114899
Drug: Iscucin® Populi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscucin® Populi (IP) strength G (0.25%)
Study: 22114899
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic solution)
Study: 18609065
Drug: Bradykinin (BK)
Normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin (BK) group received 25 microg bradykinin infusion for 7 minutes before cardiopulmonary bypass (CPB)
Study: 6701925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and radiotherapy
Study: 9388514
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of new drugs and radiotherapy
Study: 2286468
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 g single oral dose)
Study: 2286468
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (400 mg twice daily for five days)
Study: 7013868
Drug: Chemotherapy protocol
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy protocol combining adriamycin (40 mg/m2 on day 1), vincristine (1.2 mg/m2 on day 2), cyclophosphamide (400 mg/m2 on days 3, 4, 5), 5 fluorouracil (500 mg/m2 on days 3, 4, 5) followed by cyclophosphamide (100 mg/m2/day for 7 days), melphalan (2.5 mg/m2/day for 7 days), methotrexate (25 mg/m2/week for 3 weeks) with 3 applications of living BCG
Study: 7013868
Drug: Chemotherapy protocol
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy protocol without BCG
Study: 26546067
Drug: ACHD-CARE intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACHD-CARE intervention (group psychosocial intervention delivered during eight 90-minute weekly sessions)
Study: 16449211
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day for 1 week (group B)
Study: 16449211
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (group A)
Study: 11772156
Drug: Collagenase-containing ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase-containing ointment (Novuxol)
Study: 7942234
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (1 litre daily)
Study: 3281997
Drug: Ketotifen, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 1 mg in the evening during 1 week
Study: 3281997
Drug: Ketotifen, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 1 mg, twice daily, during 3 weeks
Study: 27855265
Drug: AVG intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AVG intervention (Xbox 360), played twice per week for 60 minutes over 12 weeks
Study: 24839883
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) at optimized doses of 30, 50, or 70 mg per day
Study: 23331528
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 100 μg once or twice daily
Study: 23331528
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg once or twice daily
Study: 20118486
Drug: Steroid exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid exposure
Study: 18787325
Drug: Two-compound scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound scalp formulation (calcipotriol 50 microg/g plus betamethasone dipropionate 0.5 mg/g)
Study: 18787325
Drug: Calcipotriol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 microg/g)
Study: 12832684
Drug: Fluticasone 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 1000 micro g
Study: 12832684
Drug: Beclomethasone 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 1000 micro g
Study: 10973837
Drug: Eptifibatide treatment
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide treatment in patients with significant CAD
Study: 10973837
Drug: Eptifibatide treatment
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide treatment in patients with mild CAD
Study: 10973837
Drug: Eptifibatide treatment
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide treatment in patients with no CAD
Study: 3099944
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g amoxycillin syrup
Study: 24373307
Drug: 3 dose
Normalized name: Hep A, ped/adol, 3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 dose IM priming schedule
Study: 23770132
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg · kg(‐1) · day(‐1))
Study: 16319477
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid prednicarbat plus wet‐wrap dressing
Study: 16319477
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid prednicarbat alone
Study: 10830159
Drug: Explanatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Explanatory therapy
Study: 10830159
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list followed by explanatory therapy
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 mg)
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 to 4 mg)
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 mg) with caffeine (1%)
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 mg) during vasomotor phenomena
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 mg) with fenoxazoline
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 mg) during acute viral rhinitis
Study: 1370568
Drug: Intravenous procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procaine and low‐molecular‐weight dextran
Study: 6129077
Drug: Prazosin and
Normalized name: prazosin and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin and Phenoxybenzamine (chronic therapy)
Study: 31451249
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml apple vinegar per day for 8 weeks
Study: 26897443
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (regular insulin)
Study: 20432399
Drug: sc enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc enoxaparin with protocol-mandated IV enoxaparin bolus (0.3 mg/kg)
Study: 12450026
Drug: Dynamic autoregulatory
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic autoregulatory index (ARI) tests performed every 12 hours during the first 5 days postinjury and daily during the next 5 days
Study: 7778318
Drug: Camonagrel (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camonagrel (800 mg orally)
Study: 7778318
Drug: Camonagrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camonagrel (10 mg/kg i.v.) in cats
Study: 7778318
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 mg/kg i.v.) pretreatment
Study: 7778318
Drug: L-NAME (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (100 micrograms/kg/min, i.v.) pretreatment
Study: 12952369
Drug: 17beta‐estradiol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA)
Study: 12952369
Drug: conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated equine estrogen 0.625 mg (CEE)
Study: 12952369
Drug: raloxifene HCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene HCI 60 mg
Study: 12952369
Drug: non‐users of
Approvals — FDA: no, EMA: no, PMDA: no
Description: non‐users of replacement therapy
Study: 11075556
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg.kg‐1
Study: 11075556
Drug: Ketamine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.0 mg.kg‐1
Study: 11075556
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution 5 ml (control group)
Study: 1440804
Drug: Mefloquine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 15 mg/kg
Study: 1440804
Drug: Mefloquine 25
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 25 mg/kg
Study: 31083855
Drug: Tele-nursing follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-nursing follow-up (phone by nurses for 12 weeks, twice a week for the first month and once a week for the following two months)
Study: 27431234
Drug: Tribendimidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine 400 mg
Study: 27431234
Drug: Tribendimidine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (various doses)
Study: 27431234
Drug: Tribendimidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (25 to 200 mg)
Study: 24762684
Drug: Non-bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-bismuth quadruple therapy for 7 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, tinidazole 500 mg given twice daily)
Study: 24762684
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for 7 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg given twice daily)
Study: 24762684
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for 10 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg given twice daily)
Study: 24762684
Drug: Non-bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-bismuth quadruple therapy
Study: 24762684
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for 7 days
Study: 22356304
Drug: Sucralfate-steroid retention
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate-steroid retention enema
Study: 16183654
Drug: Postcards intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postcards intervention (eight postcards over 12 months) along with standard treatment